BIOCOM CALIFORNIA PAC | PubSys CalAccessCommittee header
BIOCOM CALIFORNIA PAC
Active cycles
2001-20022003-20042005-20062007-20082009-20102011-20122013-20142015-20162017-20182019-20202021-20222023-20242025-2026
Panel 2 • Finance overview
Committee finance snapshot
Scope: 2025-2026 cycle
- Raised
- $181,499Dated receipts + reported unitemized intervals
- Spent
- $140,379
- Net activity
- $41,120
Receipt coverage evidence (29 components)
- Filing 3169368, amendment 0, A: 2026-01-01 – 2026-06-30; $2,174.60; accepted · whole interval in window
- Filing 3169368, amendment 0, F460: 2026-01-01 – 2026-06-30; amount unknown; accepted · whole interval in window
- Filing 3067796, amendment 0, A: 2025-01-01 – 2025-06-30; $2,470.00; accepted · whole interval in window
- Filing 3169368, amendment 0, C: 2026-01-01 – 2026-06-30; $0.00; accepted · whole interval in window
- Filing 3067796, amendment 0, C: 2025-01-01 – 2025-06-30; $0.00; accepted · whole interval in window
- Filing 3108725, amendment 0, C: 2025-07-01 – 2025-12-31; $0.00; accepted · whole interval in window
- Filing 3108725, amendment 0, A: 2025-07-01 – 2025-12-31; $2,384.25; accepted · whole interval in window
- Filing 3108725, amendment 0, F460: 2025-07-01 – 2025-12-31; amount unknown; accepted · whole interval in window
- Filing 3067796, amendment 0, F460: 2025-01-01 – 2025-06-30; amount unknown; accepted · whole interval in window
- Filing 3093466, amendment 0, F497P1: Receipt date 2025-07-03; $582.50; covered_by_regular_filing
- Filing 3093466, amendment 0, F497P1: Receipt date 2025-07-07; $227.50; covered_by_regular_filing
- Filing 3093466, amendment 0, F497P1: Receipt date 2025-07-08; $425.00; covered_by_regular_filing
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 42.8% of dated attributable receipts.
Dominant category: Operations at 91.2% of spending.
Funding distribution
$5,000+
Count: 11
Share: 42.8%
Amount: $74,600
$1,000 - $4,999
Count: 27
Share: 30.5%
Amount: $53,147
$500 - $999
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings pageBroad-base funded, Non-media-led spender, Active in 2025-2026 cycle.
Money over time
Dated receipts only; unitemized reporting intervals are not allocated to dates.
ContributionsExpenditures
Jan 2025Jul 2025Dec 2025Jun 2026
Count: 24
Share: 9.4%
Amount: $16,384
$100 - $499
Count: 100
Share: 17.4%
Amount: $30,338
$1 - $99
Count: 1
Share: 0%
Amount: $0
| Contribution bucket | Count | Amount | Share of dated receipts |
|---|
| $5,000+ | 11 | $74,600 | 42.8% |
| $1,000 - $4,999 | 27 | $53,147 | 30.5% |
| $500 - $999 | 24 | $16,384 | 9.4% |
| $100 - $499 | 100 | $30,338 | 17.4% |
| $1 - $99 | 1 | $0 | 0% |
Spending categories
Operations
Amount: $128,009
Share: 91.2%
Consulting
Amount: $8,497
Share: 6.1%
Field
Amount: $3,754
Share: 2.7%
Media
| Category | Amount | Share of spent |
|---|
| Operations | $128,009 | 91.2% |
| Consulting | $8,497 | 6.1% |
| Field | $3,754 | 2.7% |
| Media | $120 | 0.1% |
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|
| NEUROCRINE BIOSCIENCES, INC. | $25,655 | 14.7% | 4 | Mar 2, 2026 |
| SEMPRA | $10,000 | 5.7% | 2 | Apr 10, 2026 |
| ELI LILLY AND COMPANY & SUBSIDIARIES | $9,800 | 5.6% | 1 | Aug 18, 2025 |
| GILEAD SCIENCES, INC. | $9,800 | 5.6% | 1 | Mar 12, 2025 |
| NOVARTIS SERVICES, INC. | $8,000 | 4.6% | 2 | Jun 17, 2025 |
| ABBOTT LABORATORIES EMPLOYEE PAC | $5,000 | 2.9% | 1 | Dec 11, 2025 |
| AMGEN INC. STATE PAC | $5,000 | 2.9% | 1 | Mar 28, 2025 |
| BIOMARIN PHARMACEUTICAL, INC. | $5,000 | 2.9% | 1 | Nov 13, 2025 |
| UCB, INC. | $5,000 | 2.9% | 1 | Apr 24, 2025 |
| REVOLUTION MEDICINES | $3,788 | 2.2% | 2 | Apr 17, 2026 |
| BAYER CORPORATION | $3,455 | 2% | 1 | Oct 2, 2025 |
| ACADIA PHARMACEUTICALS | $3,363 | 1.9% | 2 | Apr 17, 2026 |
| THERMOFISHER SCIENTIFIC | $3,236 | 1.9% | 1 | Apr 17, 2026 |
| QUIDELORTHO | $3,180 | 1.8% | 1 | Nov 24, 2025 |
| ORGANON | $3,000 | 1.7% | 1 | Nov 21, 2025 |
| AJINOMOTO BIO-PARMA SERVICES | $2,650 | 1.5% | 1 | Apr 7, 2025 |
| EXELIXIS, INC. | $2,650 | 1.5% | 1 | Mar 19, 2025 |
| GLAUKOS CORPORATION | $2,126 | 1.2% | 1 | Jan 29, 2026 |
| CYTOKINETICS, INC. | $1,867 | 1.1% | 1 | Dec 17, 2025 |
| REVANCE THERAPEUTICS, INC. | $1,573 | 0.9% | 1 | Apr 4, 2025 |
| VIVIDION THERAPEUTICS, INC. | $1,573 | 0.9% | 1 | Jun 16, 2025 |
| ARCTURUS THERAPEUTICS | $1,438 | 0.8% | 1 | Apr 16, 2025 |
| ARCUTIS BIOTHERAPEUTICS, INC. | $1,438 | 0.8% | 1 | Jun 26, 2025 |
| BILLIONTOONE, INC. | $1,280 | 0.7% | 1 | Apr 17, 2026 |
| CRINETICS PHARMACEUTICALS, INC. | $1,280 | 0.7% | 1 | May 22, 2026 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.